Avience Biomedicals IPO

About Avience Biomedicals IPO

The public issue of the Avience Biomedicals IPO, an SME IPO, opens on Thursday, June 18, 2026 and closes on Monday, June 22, 2026. The allotment of shares will take place on Tuesday, June 23, 2026. The credit of shares to the demat account will take place on Wed, Jun 24, 2026. The initiation of refunds will take place on Wednesday, June 24, 2026. The listing of shares will take place on Thursday, June 25, 2026.

The offer consists of a fresh issue component. The fresh issue will include 0.15 crore shares of ₹30.24 crores. The total number of shares and aggregate amount are 14,53,800 shares aggregating up to ₹30 crores.

Avience Biomedicals IPO’s price band is set at ₹196 to ₹208 per share. The lot size for an application is 600 shares. The minimum amount of investment required by a retail investor is ₹2,49,600 (1,200 shares) (based on upper price). The minimum lot size investment for HNI is 3 lots (1,800 shares), amounting to ₹3,74,400.

Avience Biomedicals has emerged as an innovative diagnostics solutions provider. Recognised as a startup and a small-scale industry under MSME, the company is committed to empowering healthcare professionals with advanced technology.

Objectives of Avience Biomedicals IPO

• Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
• Funding the working capital requirement of the company.
• To meet the general corporate purposes.

Industry Outlook

The diagnostic market in India consists of both unorganised and well-established players. However, the diagnostic market is fragmented and includes standalone centres, private hospitals, and government hospital laboratories. Due to the market fragmentation, the capacity, quality, and scalability of labs may be at risk. However, this fragmentation provides an opportunity for newer business models to evolve. For instance, innovation and competitive pricing in the diagnostics sector are constantly being driven by the entry of new pharmaceutical firms, hospitals, telemedicine providers, and online aggregators. About three-quarters of the market is based in the urban region, leaving companies to expand to other regions in India. In recent years, this has led to establishing diagnostic services in tier 2 and 3 cities with access to advanced technologies and affordable infrastructure. These cities provide a feasible frontier for diagnostic companies due to the growing population and varying healthcare needs. Besides, the government is prioritising regulations to improve market efficiency in the near future.

About Avience Biomedicals

Avience Biomedicals, established in 2019 amidst the global challenges of the COVID-19 pandemic, has emerged as an innovative diagnostics solutions provider. Recognised as a startup and a small-scale industry under MSME, the company is committed to empowering healthcare professionals with advanced technology. Avience Biomedicals commenced its journey by producing essential diagnostic kits such as Viral Transport Media (VTM), COVID, Human Immunodeficiency Viruses (HIV), HBsAg, Malaria, Dengue, and others, aimed at aiding medical institutions with affordable and high-quality solutions. The company has expanded its product range from IVD rapid test kits to include a comprehensive line of medical devices such as serology products, biochemistry analysers, and biochemistry reagents, demonstrating a dedication to addressing diverse healthcare needs. Being purely focused on the B2B and B2G markets, their products cater to pathology labs, microbiology labs, hospitals, and research centres across India and internationally. In addition to manufacturing, the company also acts as a distributor and trader of medical equipment.

Strengths of Avience Biomedicals

• Innovative product portfolio.
• Strong regulatory compliance.
• Established reputation.
• Talented workforce.
• Efficient operations.

Risks of Avience Biomedicals

• Failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose them to litigation or other liabilities.
• They are dependent on certain customers for a portion of their revenues.
• They rely on suppliers for medical devices and equipment manufacturers for their trading goods.
• Their financial statements as restated are prepared and signed by the peer review auditor who is not statutory auditors of the company as required under the provisions of ICDR.
• Their business derives a significant portion of its revenue from the trading sector, and any potential instability in this area could pose a risk to their overall performance.

Anchor Investor Bidding Date: Wednesday June 17, 2026

Registrar Details
Skyline Financial Services Private Limited
Email: ipo@skylinerta.com
Tel.: 011-40450193-197

Book Running Lead Manager
Fintellectual Corporate Advisors Private Limited

Avience Biomedicals Contact Details
C-11, Block-C Community Centre, Janakpuri A-3,
Delhi, New Delhi, 110058
Email: info@avienbio.com
Phone: 1800-12-04-636

Avience Biomedicals Business Model

The company earns its revenue through the following sources:

• Producing essential diagnostic kits for diseases such as Viral Transport Media (VTM), COVID, Human Immunodeficiency Virus (HIV), HBsAg, Malaria, Dengue, and others, aimed at aiding medical institutions with affordable and high-quality solutions.
• Offering a product range that extends from IVD rapid test kits to a comprehensive line of medical devices such as serology products, biochemistry analysers, and biochemistry reagents, showcasing a commitment to addressing various healthcare needs.
• Operating as distributors and traders of medical equipment.

Avience Biomedicals Growth Trajectory

Avience Biomedicals’s Total Income for FY26 was ₹41.943 crores, whereas in FY25 and FY24 it was ₹45.967 crores and ₹24.373 crores, respectively. (Consolidated)

The Profit After Tax for FY26 was ₹5.740 crores, whereas in FY25 and FY24 it was ₹7.232 crores and ₹2.141 crores, respectively.

Their EBITDA for January 31, 2026 was ₹10.335 crores, whereas in FY25 and FY24 it was ₹11.410 crores and ₹4.075 crores, respectively.

Avience Biomedicals Market Position

The company has built a strong reputation for reliability, quality standards, and exceptional customer satisfaction both within the domestic market and on the global stage. As a channel partner for Mindray, they benefit from the synergy of their global reputation, while simultaneously contributing to their own standing in markets worldwide.

As of 31 March 2026, the company’s Total Income, Profit After Tax, and EBITDA for January 31,2026 were ₹41.943 crores, ₹5.740 crores, and ₹10.335 crores, respectively.

How to apply for Avience Biomedicals IPO?

• Step 1: Log in to your Kotak Neo Demat account - Log in to your Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details - Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID - After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification - Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request - Your funds will be blocked once you approve the mandate request on your UPI.